Suspension of trading

Spexis AG Stock Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Market Closed - Swiss Exchange 03:36:37 20/03/25 am AEDT 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 31/03/2022
Director of Finance/CFO - 01/08/2024
Director TitleAgeSince
Chairman 70 20/11/2019
Director/Board Member 65 01/06/2013
Director/Board Member 80 30/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
+2.13%-2.13%+17.29%-8.92% 66.32B
+1.23%+2.80%+37.51%+202.14% 52.6B
+10.08%+51.80%+51.80%+51.80% 43.27B
-1.32%-6.34%-56.98%-57.24% 38.64B
+1.09%-1.62%+52.84%-26.84% 29.62B
+0.96%+0.38%+66.97%+85.47% 23.31B
-4.00%-11.48%+60.84%-55.53% 22.62B
-1.21%-4.51%+2.22%+174.24% 20.22B
-0.22%-0.95%+61.97%+123.78% 16.29B
Average +0.96%-1.33%+20.56%+38.97% 34.77B
Weighted average by Cap. +1.65%-0.65%+27.86%+49.70%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B